Article info
Review
Optic neuritis with potential for poor outcome
- Correspondence to Dr Sarah A Cooper, Neurology Department, University Hospitals Sussex NHS Foundation Trust, Brighton, UK; sarah.cooper56{at}nhs.net
Citation
Optic neuritis with potential for poor outcome
Publication history
- Accepted January 16, 2022
- First published May 2, 2022.
Online issue publication
May 17, 2022
Article Versions
- Previous version (2 May 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations
- Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease
- Myelin oligodendrocyte glycoprotein (MOG) antibody-associated longitudinally extensive transverse myelitis (LETM) and primary Sjogren syndrome: a rare association
- Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
- Distinct clinical characteristics of atypical optic neuritis with seronegative aquaporin-4 antibody among Chinese patients
- Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy
- Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis
- Paediatric optic neuritis: factors leading to unfavourable outcome and relapses
- Recurrent visual loss in a 64-year-old man
- A practical approach to the diagnosis of spinal cord lesions